Destiny Pharma focuses on the scientific discovery and clinical development of highly innovative antibacterials.

We have built an international collaborative network with high quality external research institutions and our science is enhanced by strong relationships with world-class opinion leaders.

Our innovative development process has already produced the XF series – revolutionary new antibacterials.

Evidence shows that the likelihood of resistance developing to these drugs is very remote – offering totally new means to prevent, and treat, infections caused by drug-resistant bacteria such as MRSA.